DLBCL

Gilles Salles, MD, PhD, discussed sequencing of CD-19 directed therapies for a 74-year-old patient with diffuse large B-cel lymphoma during a Targeted Oncology Case-Based Peer Perspective Roundtable event.

Caron Jacobson, MD, discusses the survival and response data for axicabtagene ciloleucel from the phase 1/2 ZUMA-1 trial.

The novel ROR1-targeted antibody-drug conjugate VLS-101 induced encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile as treatment of heavily pretreated patients with mantle cell lymphoma and diffuse large B-cell lymphoma.

A post-hoc analysis of the SADAL trial showed there was clinical benefit with selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma regardless of age.

In an interview with Targeted Oncology, Ajeet Gajra, MD, FACP, vice president, Cardinal Health, discussed the ongoing challenges community oncologists face with prescribing CAR T-cell therapy to patients with relapsed/refractory diffuse large B-cell lymphoma.

Loretta J. Nastoupil, MD, discussed the use of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma during a Targeted Oncology Case Based Peer Perspectives event.

During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.

Kami J. Maddocks, MD, discussed the efficacy and safety of tafasitamab in combination with lenalidomide as treatment of a 74-year-old man with diffuse large B-cell lymphoma. The treatment option was discussed with a group of oncologists during a Targeted Oncology Case Based Peer Perspective event.

The FDA has accepted a Biologic License Application for loncastuximab tesirine as treatment of relapsed or refractory diffuse large B-cell lymphoma and granted it a Priority Review designation.

In an interview with Targeted Oncology, Nilanjan Ghosh, MD, discussed the current challenges in using CAR T-cell therapy as treatment of patients with DLBCL and considers the next steps for this research.

Nilanjan Ghosh, MD, discusses the effect coronavirus disease 2019 had on using chimeric antigen receptor T-cell therapy to treat patients with diffuse large B-cell lymphoma.

In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study demonstrated that certain gene expressions are associated with response to DPX-Survivac plus pembrolizumab and intermittent, low-dose cyclophosphamide.

In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.